Navigation Links
Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
Date:10/16/2007

p>

About Insomnia

Good quality and refreshing sleep is a prerequisite for continued good health and daily functioning. Insomnia patients suffer from a) difficulty falling asleep; b) difficulty maintaining sleep due to waking up frequently during the night with difficulty returning to sleep or due to waking up at early hours and c) unrefreshing sleep. In 2005, the Sleep in America poll found that 54% of the adult population reported symptoms of insomnia at least a few nights a week. However, only a fraction of patients are diagnosed, with even fewer using a sleep aid. The insomnia market is estimated to be worth US$ 6.1 billion across the major markets in 2007, and is set to be impacted by the launch of new drug classes (Datamonitor, Pipeline Insight: Insomnia, April 2007). Physicians highlight that the ideal insomnia drug has the ability to induce, maintain and improve the quality of sleep without causing next day hang-over and the absence of addiction liabilities. Key unmet needs include improvements in sleep maintenance and more effective treatments in the elderly population. The entry of novel treatments with differentiated profiles in terms of dosage, mode of action and clinical profile are expected to accelerate growth within the market.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 30
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Vienna, VA (PRWEB) June 18, 2013 As ... the increase in need for surgical equipment during childbirth comes ... the child from within the mother when she is unable ... difficult deliveries, they are associated with higher rates of complication ... addition to being harmful to the mother and child, forceps ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and ... the drug delivery partnering deals and agreements entered into ... report provides a detailed understanding and analysis of how ... majority of deals are discovery or development stage whereby ... to license the license drug delivery technology. These deals ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Parker ... protecting the rights of victims injured by defective medical ... review of Medtronic’s Infuse bone graft products are now ... a medical journal, the two studies serve up two ... effectiveness” when comparing Infuse and the traditional bone graft; ...
(Date:6/18/2013)... ENT and Allergy Associates, LLP (ENTA) does not ... , New York/New Jersey’s premier ear, nose, throat, ... offering superior healthcare to children and adults in hundreds ... York area-only considers adding to its current footprint when ... the right communities to serve, the right locations from ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3
... between micronutrient supplementation and reduced risk of recurrence during ... June 1 issue of The Journal of Infectious Diseases, ... tuberculosis therapy, once common before the advent of anti-TB ... therapy in most low-income countries even though poor nutrition ...
... Johnson &,Johnson will participate in the Morgan Stanley ... The Ritz-Carlton in Key Biscayne,Florida. Dominic Caruso, Vice ... Company in a session scheduled at 2:20 p.m.,(Eastern ... investors and other interested parties,by accessing the Johnson ...
... that are helping doctors diagnose and treat lung ... Lung Cancer Conference jointly organized by the European ... Association for the Study of Lung Cancer (IASLC) ... No. 81O; Friday 25th April, 16:30), Israeli researchers ...
... autism are increasingly turning to sensory integration treatment ... and theyre seeing good results. In 2007, 71 ... treatment used sensory integration methods, and 91 percent ... from Temple University researchers, presented this month at ...
... (NYSE: HRC ) fiscal 2008 second quarter earnings ... invited to view its webcast the,following morning on Wednesday, ... Release: Hill-Rom Holdings, Inc.,s Fiscal 2008 Second Quarter,Earnings Release ... released to,the public after the NYSE close on Tuesday, ...
... in OTC Private Label Market, PRINCETON, N.J., ... owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced,today ... U.S. Food and Drug,Administration to manufacture and market ... Oral Solution,(Hives-Relief), 1 mg/mL (OTC). The Office of ...
Cached Medicine News:Health News:Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence 2Health News:New genetic techniques to combat lung cancer 2Health News:Autistic mannerisms reduced by sensory treatment 2Health News:Autistic mannerisms reduced by sensory treatment 3Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast 2Health News:Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution 2
(Date:6/18/2013)... 18, 2013 Apama Medical, a privately ... of next-generation atrial fibrillation technologies, today announced the ... US Patent and Trademark Office (USPTO), titled "Low ... assemblies for use on expandable structures such as ... procedures. "We are grateful to the ...
(Date:6/18/2013)... Calif. , June 18, 2013  Isis Pharmaceuticals, Inc. ... today announced that management will present a general corporate update ... Open House on Tuesday, June 25 at 2:10 p.m. Pacific ... The agenda for the meeting is as follows: 2:00 p.m. ... of record as of April 26, 2013) 2:10 p.m. – ...
(Date:6/17/2013)... , June 17, 2013 Velplex, LLC announced ... a technology platform that connects buyers and sellers of ... an industry leader. Why? It,s because ... are intimately familiar with the dental industry. They have ... and have diligently worked to negotiate some of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
... The Clariflex® Intraocular Lens is indicated ... years of age or older in whom ... IOL is a third-generation IOL design made ... is designed both to reduce internal reflections ...
... Lenses: The Bausch & Lomb PMMA Posterior Chamber ... primary implantation for the visual correction of aphakia ... where a cataractous lens has been removed by ... be placed in the ciliary sulcus or capsular ...
... USIOL lenses are manufactured using ... processes. Perspex CQ UV PMMA ... multi-piece and single piece lenses. ... in both nonphaco and phaco ...
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: